XtalPi (HKG:2228) expects to return to profit for the first half of 2025, according to a Hong Kong bourse filing Tuesday.
The pharma research firm expects to post at least 50 million yuan in net profit for the six months ended June 30, compared with a loss of 1.24 billion yuan a year ago.
Revenue for the period is expected to rise at least 387% year over year to 500 million yuan, the company said.
XtalPi's financial results are due by the end of August.